Q2 2024 Oncopeptides AB Earnings Call Transcript
Key Points
- Revenue for the second quarter increased by 60% from SEK5.1 million to SEK8.2 million, marking the best month on record in June.
- Pepaxti has shown strong early interest in Spain, with the first sale announced in May and positive feedback from Spanish doctors.
- The company has expanded its market access efforts in France and other European markets, with a value dossier submitted in France.
- Oncopeptides AB has signed an agreement with Veld Pharma GmbH for named patient sales in Africa, focusing on South Africa.
- The company has a strong cash position of SEK383 million at the end of the second quarter, bolstered by a successful rights issue.
- Despite the revenue increase, the company is still far from profitability, which is targeted for 2026.
- The market access process in Europe is controlled by payers, making the timeline for revenue generation uncertain.
- The company has no ongoing clinical studies, and future clinical trials for OPSP1 are not included in the current financial plan.
- There is a significant increase in noncurrent assets and equity due to the restructuring of the patent portfolio, which may affect financial stability.
- The company's profitability plan relies heavily on sales from specific European markets, and any delays in market access could impact financial targets.
Welcome to this presentation of our report for the second quarter of 2024. This is our standard disclaimer. With me, I have Henrik Bergentoft, who will give a financial update. I will then come back to an update of our European commercialization process and our next step value drivers. But first, starting off with some key highlights.
I am happy to announce that the revenue for the second quarter increased from SEK5.1 million last quarter to SEK8.2 million, the second quarter. This is an increase of 60% compared to the first quarter. As June was our best month on record, I expect this trajectory to continue into Q3 and beyond.
Pepaxti has now been available in Spain since May 1 and during the same month, we announced the first sale of the drug. The early interest in Pepaxti from Spanish doctors confirms that the positive clinical experience from our clinical trials is supporting the understanding of how Pepaxti can help patients.
And I look forward to see sales pick up once we have fully
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
